HSBC Starts Teva Pharma (TEVA) at Buy, 'innovative medicine division to become a driver of growth'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. CVS
10. SPY

Go back to HSBC Starts Teva Pharma (TEVA) at Buy, 'innovative medicine division to become a driver of growth'

Teva Pharma (TEVA) and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma

December 14, 2023 8:34 AM EST

Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) and Biolojic Design Ltd. ("Biolojic") today announced an exclusive license agreement to develop a potential novel antibody-based therapy for the treatment of Atopic Dermatitis and Asthma.

BD9 is a dual specific antibody that can block both TSLP (Thymic stromal lymphopoietin) and IL-13, and has the potential to deliver treatment across typically TH2-driven inflammatory diseases, such as atopic dermatitis and asthma. Existing drugs currently approved by health authorities focus on only one of these two drivers of inflammation, and do not respond to pathway... More